JP2018536707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536707A5 JP2018536707A5 JP2018543001A JP2018543001A JP2018536707A5 JP 2018536707 A5 JP2018536707 A5 JP 2018536707A5 JP 2018543001 A JP2018543001 A JP 2018543001A JP 2018543001 A JP2018543001 A JP 2018543001A JP 2018536707 A5 JP2018536707 A5 JP 2018536707A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight percent
- cancer
- coating
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 131
- 238000000034 method Methods 0.000 claims description 43
- 239000011248 coating agent Substances 0.000 claims description 29
- 238000000576 coating method Methods 0.000 claims description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 239000003826 tablet Substances 0.000 claims description 25
- 238000007906 compression Methods 0.000 claims description 23
- 230000006835 compression Effects 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- 229960000894 sulindac Drugs 0.000 claims description 16
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 16
- FJPAMFNRCFEGSD-UHFFFAOYSA-N eflornithine hydrochloride monohydrate Chemical compound O.Cl.NCCCC(N)(C(F)F)C(O)=O FJPAMFNRCFEGSD-UHFFFAOYSA-N 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 239000000314 lubricant Substances 0.000 claims description 10
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 229940000425 combination drug Drugs 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229920000193 polymethacrylate Polymers 0.000 claims description 6
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- IWVKTOUOPHGZRX-UHFFFAOYSA-M methyl 2-methylprop-2-enoate;2-methylprop-2-enoate Chemical compound CC(=C)C([O-])=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-M 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002702 enteric coating Substances 0.000 claims description 3
- 238000009505 enteric coating Methods 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 2
- 229940063655 aluminum stearate Drugs 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- SXFILQHETIJGQZ-UHFFFAOYSA-N but-3-enoic acid;phthalic acid Chemical compound OC(=O)CC=C.OC(=O)C1=CC=CC=C1C(O)=O SXFILQHETIJGQZ-UHFFFAOYSA-N 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 229940078456 calcium stearate Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 229940080350 sodium stearate Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- GLVYLTSKTCWWJR-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1C(O)=O GLVYLTSKTCWWJR-UHFFFAOYSA-N 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 229960002759 eflornithine Drugs 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010020864 Hypertrichosis Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021186911A JP7592001B2 (ja) | 2015-10-30 | 2021-11-17 | エフロルニチンとスリンダクの固定用量複合製剤 |
| JP2024079276A JP2024102339A (ja) | 2015-10-30 | 2024-05-15 | エフロルニチンとスリンダクの固定用量複合製剤 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248810P | 2015-10-30 | 2015-10-30 | |
| US62/248,810 | 2015-10-30 | ||
| US201662358698P | 2016-07-06 | 2016-07-06 | |
| US62/358,698 | 2016-07-06 | ||
| EP16306429.8 | 2016-10-28 | ||
| EP16306429 | 2016-10-28 | ||
| EP16306430 | 2016-10-28 | ||
| EP16306430.6 | 2016-10-28 | ||
| PCT/US2016/059689 WO2017075576A1 (en) | 2015-10-30 | 2016-10-31 | Eflornithine and sulindac, fixed dose combination formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021186911A Division JP7592001B2 (ja) | 2015-10-30 | 2021-11-17 | エフロルニチンとスリンダクの固定用量複合製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018536707A JP2018536707A (ja) | 2018-12-13 |
| JP2018536707A5 true JP2018536707A5 (OSRAM) | 2019-12-05 |
Family
ID=57256487
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543001A Withdrawn JP2018536707A (ja) | 2015-10-30 | 2016-10-31 | エフロルニチンとスリンダクの固定用量複合製剤 |
| JP2021186911A Active JP7592001B2 (ja) | 2015-10-30 | 2021-11-17 | エフロルニチンとスリンダクの固定用量複合製剤 |
| JP2024079276A Pending JP2024102339A (ja) | 2015-10-30 | 2024-05-15 | エフロルニチンとスリンダクの固定用量複合製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021186911A Active JP7592001B2 (ja) | 2015-10-30 | 2021-11-17 | エフロルニチンとスリンダクの固定用量複合製剤 |
| JP2024079276A Pending JP2024102339A (ja) | 2015-10-30 | 2024-05-15 | エフロルニチンとスリンダクの固定用量複合製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10973790B2 (OSRAM) |
| EP (1) | EP3368029A1 (OSRAM) |
| JP (3) | JP2018536707A (OSRAM) |
| KR (2) | KR20180069068A (OSRAM) |
| CN (1) | CN108366982A (OSRAM) |
| AU (1) | AU2016343851B2 (OSRAM) |
| BR (1) | BR112018008651A2 (OSRAM) |
| CA (1) | CA3003149C (OSRAM) |
| CL (1) | CL2018001157A1 (OSRAM) |
| CO (1) | CO2018005491A2 (OSRAM) |
| HK (1) | HK1258284A1 (OSRAM) |
| IL (1) | IL259009A (OSRAM) |
| MA (1) | MA43114A (OSRAM) |
| MX (1) | MX390899B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108366982A (zh) | 2015-10-30 | 2018-08-03 | 癌症预防制药股份有限公司 | 依氟鸟氨酸和舒林酸，固定剂量的组合制剂 |
| NZ752894A (en) * | 2016-10-06 | 2023-05-26 | Orbus Therapeutics Inc | Formulations for administration of eflornithine |
| US10945981B2 (en) | 2019-05-17 | 2021-03-16 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
| CN119909027B (zh) * | 2025-01-21 | 2025-11-18 | 福安药业集团宁波天衡制药有限公司 | 一种稳定的舒林酸片及其制备方法 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4330559A (en) | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| US4309442A (en) * | 1977-07-11 | 1982-01-05 | Merrell Toraude Et Compagnie | Method for controlling fertility in mammals |
| US4499072A (en) | 1982-11-29 | 1985-02-12 | Merrell Dow Pharmaceuticals Inc. | Process for treating diseases with ODC inhibitors |
| US4859452A (en) | 1986-01-17 | 1989-08-22 | Board Of Regents, The University Of Texas System | Methods for the reduction of difluoromethylornithine associated toxicity |
| US4925835A (en) | 1986-05-01 | 1990-05-15 | Sloan-Kettering Institute For Cancer Research | Aziridinyl putrescine containing compositions and their uses in treating prostate cancer |
| US5002879A (en) | 1986-05-06 | 1991-03-26 | Merrell Dow Pharmaceuticals | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor |
| FR2706255B1 (fr) | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| CA2241896A1 (en) * | 1996-11-01 | 1998-05-14 | Ze'ev Shaked | Sustained release formulation containing dfmo |
| US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| US6258845B1 (en) | 1998-03-28 | 2001-07-10 | The Regents Of The University Of California | DFMO and sulindac combination in cancer chemoprevention |
| US7700568B2 (en) | 1998-06-30 | 2010-04-20 | Sloan-Kettering Institute For Cancer Research | Uses of DNA-PK |
| JP2002533404A (ja) | 1998-12-23 | 2002-10-08 | ジー・ディー・サール・アンド・カンパニー | 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法 |
| US20050037090A1 (en) | 1998-12-23 | 2005-02-17 | Mckearn John P. | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent |
| US6753422B2 (en) | 1999-03-01 | 2004-06-22 | O'brien Thomas G. | Odc allelic analysis method for assessing carcinogenic susceptibility |
| AU5140300A (en) | 1999-05-17 | 2000-12-05 | Ilex Oncology, Inc. | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
| US6602910B2 (en) | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
| WO2001068076A2 (en) | 2000-03-07 | 2001-09-20 | Ilex Oncology, Inc. | D-enantiomer of dfmo and methods of use thereof for treating cancer |
| AU2001285232A1 (en) | 2000-08-24 | 2002-03-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| GB0125492D0 (en) * | 2001-10-24 | 2001-12-12 | Astrazeneca Ab | Formulation |
| AU2002343609B2 (en) | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| EP1575584A4 (en) * | 2002-11-29 | 2006-02-01 | Forest Laboratories | METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON |
| US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| CN101257800B (zh) * | 2005-07-18 | 2012-07-18 | 好利用医疗公司 | 包含法莫替丁和布洛芬的药物 |
| US9072778B2 (en) | 2005-12-20 | 2015-07-07 | University Of Hawaii | Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors |
| CA2657928C (en) * | 2006-07-18 | 2014-12-02 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| JO3272B1 (ar) | 2007-07-19 | 2018-09-16 | Takeda Pharmaceuticals Co | مستحضر صلب يشمل ألوجليبتين وميتفورمين هيدروكلوريد |
| WO2009015981A2 (en) | 2007-08-01 | 2009-02-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treatment of pediatric tumors |
| WO2009022670A1 (ja) * | 2007-08-10 | 2009-02-19 | Takeda Pharmaceutical Company Limited | 速崩壊性錠剤 |
| WO2009048932A2 (en) | 2007-10-09 | 2009-04-16 | Children's Medical Center Corporation | Methods to regulate mirna processing by targeting lin-28 |
| WO2009052518A2 (en) * | 2007-10-19 | 2009-04-23 | Aspen Benefits Group, Llc | Methods and compositions directed to reduction of facial hair hirsutism in females |
| AU2009221765B2 (en) | 2008-03-05 | 2015-05-07 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
| US20100120727A1 (en) * | 2008-11-12 | 2010-05-13 | Kyphia Pharmaceuticals, Inc. | Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof |
| WO2010077653A2 (en) | 2008-12-08 | 2010-07-08 | The Procter & Gamble Company | Personal care composition in the form of an article having a hydrophobic surface-resident coating |
| PT2430452E (pt) | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
| CA2762391C (en) | 2009-05-20 | 2017-02-07 | Ranbaxy Laboratories Limited | Liquid dosage forms of isotretinoin |
| CN101898978A (zh) | 2009-05-31 | 2010-12-01 | 徐锋 | 依氟鸟氨酸前药和偶合物及其使用方法 |
| US20110256161A1 (en) | 2010-04-19 | 2011-10-20 | Aminex Therapeutics Inc. | Methods for enhancing immune response |
| WO2011135459A2 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| EP2568978B1 (en) | 2010-05-14 | 2019-04-24 | Arizona Board of Regents on Behalf of University of Arizona | Cancer prevention and treatment based on dietary polyamine content |
| US8853423B2 (en) * | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| US9315585B2 (en) | 2010-06-19 | 2016-04-19 | Memorial Sloan Kettering Cancer Center | Anti-GD2 antibodies |
| PL2912193T3 (pl) | 2012-10-29 | 2019-03-29 | Arizona Board Of Regents On Behalf Of University Of Arizona | Markery predykcyjne dla terapii przeciwnowotworowej z użyciem inhibitora poliaminy |
| GB2513299A (en) | 2013-03-12 | 2014-10-29 | Cellact Pharma Gmbh Biomedizinzentrum | Compounds for targeting cancer stem cells |
| KR102286386B1 (ko) * | 2013-10-07 | 2021-08-05 | 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 언리미티드 컴퍼니 | 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제 |
| KR20150079373A (ko) * | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| CA2952771A1 (en) | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| WO2016130918A1 (en) | 2015-02-12 | 2016-08-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating neuroblastoma |
| CN108366982A (zh) * | 2015-10-30 | 2018-08-03 | 癌症预防制药股份有限公司 | 依氟鸟氨酸和舒林酸，固定剂量的组合制剂 |
| WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
-
2016
- 2016-10-31 CN CN201680071715.3A patent/CN108366982A/zh active Pending
- 2016-10-31 MA MA043114A patent/MA43114A/fr unknown
- 2016-10-31 JP JP2018543001A patent/JP2018536707A/ja not_active Withdrawn
- 2016-10-31 KR KR1020187015233A patent/KR20180069068A/ko not_active Ceased
- 2016-10-31 MX MX2018005350A patent/MX390899B/es unknown
- 2016-10-31 KR KR1020247034905A patent/KR20240162560A/ko not_active Ceased
- 2016-10-31 CA CA3003149A patent/CA3003149C/en active Active
- 2016-10-31 AU AU2016343851A patent/AU2016343851B2/en active Active
- 2016-10-31 HK HK19100648.5A patent/HK1258284A1/zh unknown
- 2016-10-31 US US15/771,484 patent/US10973790B2/en active Active
- 2016-10-31 BR BR112018008651A patent/BR112018008651A2/pt not_active IP Right Cessation
- 2016-10-31 EP EP16794183.0A patent/EP3368029A1/en active Pending
-
2018
- 2018-04-29 IL IL259009A patent/IL259009A/en unknown
- 2018-04-30 CL CL2018001157A patent/CL2018001157A1/es unknown
- 2018-05-25 CO CONC2018/0005491A patent/CO2018005491A2/es unknown
-
2021
- 2021-03-05 US US17/193,588 patent/US11529326B2/en active Active
- 2021-11-17 JP JP2021186911A patent/JP7592001B2/ja active Active
-
2022
- 2022-11-15 US US18/055,494 patent/US11925613B2/en active Active
-
2024
- 2024-02-07 US US18/435,678 patent/US12350246B2/en active Active
- 2024-05-15 JP JP2024079276A patent/JP2024102339A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024019726A (ja) | 注意欠陥障害の処置のための方法および組成物 | |
| JP5793828B2 (ja) | フリバンセリンの製剤及びその製造方法 | |
| CN101522176B (zh) | 氟班色林的制剂及其制备方法 | |
| JP6316376B2 (ja) | アマンタジン組成物および使用方法 | |
| CN104220068B (zh) | 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物 | |
| CN101505736A (zh) | 控制释放系统及其制造方法 | |
| WO2006118265A1 (ja) | 抗痴呆薬を含有する組成物 | |
| WO2018108152A1 (zh) | 一种奥拉帕尼口服缓控释药物组合物及其用途 | |
| CN113423390B (zh) | 阿法比星制剂及其制备方法 | |
| JP2018536707A5 (OSRAM) | ||
| US11278506B2 (en) | Pharmaceutical formulation | |
| KR20170009897A (ko) | 알리사르탄 이소프록실 고체 분산체 및 이의 약제학적 조성물 | |
| CA2949164A1 (en) | Allisartan isoproxil solid dispersion and pharmaceutical composition comprising same | |
| JPWO2014171542A1 (ja) | 放出制御製剤 | |
| HK1208130A1 (en) | Extended-release levetiracetam and method of preparation | |
| KR20090091075A (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| US9132092B1 (en) | Pharmaceutical composition of doxycycline | |
| CN102112115A (zh) | 雷米普利调节释放组合物及其应用 | |
| WO2023284724A1 (zh) | 沙库巴曲缬沙坦钠缓释组合物、其制备方法及应用 | |
| JP2015503555A (ja) | ボセンタン制御放出性経口製剤 | |
| US20220249479A1 (en) | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment | |
| CN101874802B (zh) | 一种治疗高血压和高胆固醇的缓释药物组合物 | |
| KR20170001545A (ko) | 모사프리드 서방성 제제 및 모사프리드와 라베프라졸의 복합제제 | |
| JP2016504390A5 (OSRAM) | ||
| JP2013536832A (ja) | ミルナシプランの制御放出医薬組成物 |